Top Articles

EAN Scientific Panel Neuro-oncology invites you to take part in their survey:

The first case of COVID-19 infection was recorded in Brazil on Feb 25, 2020. On June 20th, official statistics reported 1 million confirmed cases, and more than 50,000 deaths. Brazil has the second highest number of cases of COVID-19 in the world, facing more than 1,000 deaths per day. However, due to underreporting among many regions in the country, the actual numbers are unknown. Besides the underestimation of the real deaths and cases, the Government recently changed the way in which the cases were reported: only new cases were reported, and not the total number of infected people or deaths. This has produced great criticism from the scientific community and the media, increasing the levels of tension under which the country has been living.

In this paper, just published in Lancet, the authors performed a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine in Wuhan, China.

From the Spanish Society of Neurology, it is our pleasure to share with our European colleagues the Handbook on COVID-19 management for Neurologists.

On June 3, we published in the Breaking News section of this site the article entitled “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” previously published in Lancet. On June 13, the article was retracted by three of the four authors.

The European Academy of Neurology has launched a taskforce on Gender and Diversity in Neurology, with the overall mission to increase awareness and improve knowledge about sex, gender, ethnic and racial differences and disparities in neurological disorders with the aim to improve the outcome of care of neurological patients.

The European Reference Networks for Rare Neurological Diseases (ERN-RND) and for Rare Neuromuscular Diseases (ERN EURO-NMD) organise joint webinars throughout the year in collaboration with EAN.

This neurology update summarises key points on caring for people with epilepsy during the COVID-19 pandemic.

Seizures appear to be a rare feature of COVID-19. Avoiding unintentional antiseizure medicine withdrawal during the COVID-19 pandemic is a potential challenge for people with epilepsy.

In this paper recently published in Nature Medicine, Leung et al. aimed to explore the importance of respiratory droplet and aerosol routes of transmission with a particular focus on coronaviruses, influenza viruses and rhinoviruses.

In this paper recently published in Annals of Neurology, Pilotto et al., described the case of a 60-year old subject with SARS-CoV-2 infection but only mild respiratory abnormalities who developed akinetic mutism due to encephalitis.

In this paper recently published in Epilepsia, Aledo-Serrano et al. evaluated the impact of the pandemic on patients with genetic, developmental and epileptic encephalopathies (DEEs) and their caregivers in Spain.

In this retrospective, multicentre study, the author systematically characterised neurological symptoms and neuroimaging features in hospitalised COVID-19 patients from multiple institutions in Italy.

In this systematic review and meta-analysis, the authors analysed studies or preprints reporting data on the psychiatric and neuropsychiatric presentations of individuals with suspected or laboratory-confirmed coronavirus infection (SARS coronavirus, MERS coronavirus, or SARS coronavirus 2).

In this retrospective, single centre cohort study, recently published in Neurology, Benussi et al., reported clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurological diseases with and without COVID-19.